Research and Markets: Examine the Latest Mergers & Acquisitions Undertaken by the Medical Devices Company - Johnson & Johnson.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47876) has announced the addition of the Espicom Business Intelligence Ltd report: Johnson & Johnson Medical Device Company Intelligence Report to their offering.

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Topics Covered Include:
Executive Summary
Overview
Strategic Focus
Product Portfolio and R&DResearch and Development
International Activities
Latin America
Europe
Asia-Pacific.
Middle East
Appendices
Appendix 1 - Financial Indicators
Financial Indicators
Appendix 2 - Key Corporate Events
Appendix 3 - Mergers And Acquisitions
Appendix 4 - Minority Investments
Appendix 5 - Divestitures
Appendix 6 - Agreements
Appendix 7 - Litigation
Index of Tables
Index of Charts
Financial Indicators

Summary

With sales of US$19.1 billion in 2005, the company's Medical Devices & Diagnostics unit is the world's largest medical device company, offering sutures and wound management products, surgical equipment, interventional and diagnostic cardiology and endovascular products, orthopaedic and spinal products, diabetes care, contact lenses and sterilisation products.

With a decentralised management approach, the business boasts a number of leading companies, including Cordis, DePuy, Ethicon, Ethicon Endo-Surgery, LifeScan, Independence Technology, Therakos and Vistakon, all of which are covered in separate sections for each company. These can be purchased individually, as well as in the main J&J profile.

Cordis - focused on interventional cardiology and peripheral and neuro vascular products, as well as electrophysiology through Biosense Webster. Cordis' main product line is its Cypher Sirolimus-Eluting Stent, the world's best-selling drug-eluting stent (DES). J&J's planned acquisition of Conor Medsystems should also provide it with new-generation bioabsorbable DES technology.

DePuy - a market leader in joint reconstruction and spinal products focused on less-invasive and durable, motion-saving solutions. The company also includes DePuy Mitek, which offers sports medicine products, and Codman & Shurtleff, that provides products for treating central nervous system disorders. It also includes recently-acquired Hand Innovations, adding technology for the fast-growing global extremities market.

Ethicon - the global market leader for sutures, which also offers surgical mesh and products for hernia repair, incontinence, gynaecology/urology and cardiac surgery. It also includes Closure Medical, a manufacture of biomaterial-based medical devices.

Ethicon Endo-Surgery (including Advanced Sterilization Products) - offers surgical instruments for minimally-invasive and traditional surgery, including surgical stapling, energy-based devices, endoscopic surgery and breast biopsy products.

Independence Technology - markets the iBOT Mobility System, an advanced gyro-balanced mobility system.

LifeScan - a market leader for blood glucose monitoring with the OneTouch brand. Also includes recently-acquired Animas, adding insulin delivery technology to the portfolio.

Therakos - offers products that use extracorporeal photopheresis, a cellular therapy first applied to patients with refractory cutaneous T-cell lymphoma.

Vistakon - the world's leading manufacturer of disposable contact lenses. The company is also planning to expand into contact lens solutions and ophthalmic pharmaceuticals, helped by expertise from J&J's planned acquisition of Pfizer's consumer pharmaceutical operations.

J&J has recently added to several of its businesses with acquisitions that complement its operations and expand their capabilities into new areas. These include Animas, rounding out LifeScan's blood glucose monitoring operations with insulin infusion capabilities, so addressing all aspects of diabetes care; and Hand Innovations, adding fracture fixation products for upper extremities to DePuy's Trauma & Extremities Group. J&J has also recently agreed to acquire Conor Medsystems. The transaction is expected to close in the first quarter of 2007. Should the acquisition go through, J&J and Cordis will have access to controlled drug delivery technology currently employed on Conor's CoStar Stent System, a paclitaxel-eluting cobalt chromium stent with a bioabsorbable polymer.

For more information visit http://www.researchandmarkets.com/reports/c47876